New RSV vaccine trial targets those over 80
⭐️ VACCINE ⭐️
Recruiting now
This study looks at how well the approved RSV vaccine Arexvy works in very elderly and frail adults aged 80 and older, compared to those aged 60-65. Researchers will measure immune responses and side effects after the first dose and a booster. The goal is to ensure this high-risk…
Phase: PHASE3 • Sponsor: Karin Karin Loré • Aim: ⭐️ VACCINE ⭐️
Last updated May 18, 2026 12:12 UTC